Disclosures for "Patients with Tardive Dyskinesia (TD) Report Improved Quality of Life Scores and Met TD Remission Criteria with Once-daily Valbenazine in KINECT-PRO™, Regardless of TD Movement Severity at Baseline"
-
Eduardo Dunayevich has received personal compensation for serving as an employee of Neurocrine Biosciences. Eduardo Dunayevich has stock in Neurocrine Biosciences.
-
Dr. Perez-Rodriguez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Perez-Rodriguez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe Pharma. The institution of Dr. Perez-Rodriguez has received research support from Neurocrine.
-
Dr. Parameswaran has received personal compensation for serving as an employee of neurocrine biosciences.
-
Morgan Bron has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.. Morgan Bron has stock in Neurocrine.
-
Ms. Franey has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.. Ms. Franey has stock in Neurocrine Biosciences, Inc..
-
Donna Sparta has nothing to disclose.
-
Ms. Gao has received personal compensation for serving as an employee of Neurocrine Biosciences. Ms. Gao has stock in Neurocrine Biosciences.
-
Hui Zhang has received personal compensation for serving as an employee of Neurocrine Bioscience Inc..
-
The institution of Ms. Mathias has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brenig Therapeutics.
-
Dr. Alva has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Alva has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for neurocrine. The institution of Dr. Alva has received research support from Neurocrine.
-
Prof. Correll has received personal compensation for serving as an employee of AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon . Prof. Correll has received personal compensation for serving as an employee of UpToDate. Prof. Correll has received personal compensation for serving as an employee of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, Terran.. Prof. Correll has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol-Meyers Squibb, Cerevel, Compass, Denovo, Eli Lilly, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, Kuleon Biosciences, LB Pharma, Lundbeck, MedInCell, Medlink, Merck, Mindpax, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatris.. Prof. Correll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie, Allergan, Angelini, Boehringer Ingelheim, Bristol-Meyers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatris.. Prof. Correll has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Janssen, Lundbeck and Otsuka. The institution of Prof. Correll has received research support from Boehringer-Ingelheim, Janssen and Takeda. Prof. Correll has received publishing royalties from a publication relating to health care.